EQT Agrees to Buy Qiagen in $10.8 Billion All-Cash Takeover
EQT has agreed to acquire German molecular testing company Qiagen in an all-cash deal valued at about $10.8 billion, marking one of the largest healthcare buyouts in Europe this year. The transaction underscores private equityโs continued appetite for stable, cash-generative life sciences assets even as higher rates and volatile markets complicate dealmaking.
